Clinical trials: Leishmaniasis
Leishmaniasis
Safety and Drug Absorption of Orally Administered Oleylphosphocholine (OlPC) in Healthy Adults
The goal of this interventional study is to assess the safety and tolerability of OlPC and to characterize the pharmacokinetics (PK) of OlPC following single, ascending doses administered orally in healthy-fed subjects.
- Trial name
- NCT06124144
- Testing
- Oleylphosphocholine
- Where
- Germany
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- University Hospital Tuebingen
Leishmaniasis
Fractional CO2 Laser With Topical Pentostam Treatment for Cutaneous Leishmaniasis.
The investigators will compare the common treatment for cutaneous leishmaniasis with intra-lesional Pentostam to fractional CO2 laser with topical application of Pentostam.
- Trial name
- NCT03009422
- Testing
- Local application pentostam, intra-lisional pentostam, fractional CO2 laser
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Tel-Aviv Sourasky Medical Center
Zika, Dengue
Defining Skin Immunity of a Bite of Key Insect Vectors in Humans
Background: Mosquitoes and similar insects called sand flies carry parasites that can cause diseases. These viruses and parasites can spread quickly and be difficult to control.
- Conditions
- Zika, Dengue, Malaria, Chikungunya
- Trial name
- NCT03641339
- Testing
- One vector feeding, Four vector feeding
- Where
- United States
- Volunteers
- 95 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Visceral Leishmaniasis
A Study to Assess Immune Response Status in Patients Before and After Treatment for Visceral Leishmaniasis
ImmStat@Cure is a multicentre observational study designed to assess the immune status of patients before and after treatment for visceral leishmaniasis. Forty patients and 30 controls will be recruited per site.
- Trial name
- NCT04342715
- Testing
- Sodium stibogluconate / paramomycin
- Where
- Kenya
- Volunteers
- 216 people, healthy volunteers welcome
- Sponsor
- University of York
Leishmaniasis, Cutaneous, Leishmaniasis
Ex Vivo Immunogenicity Screening of Vaccine Candidate Antigen Combinations in Ethiopian Patients With Leishmaniasis
This study assesses the immunoprevalence (presence of the induced T-cell response across different patients (and thus HLA types) of six prioritized IPX-derived Leishmania antigens, using Good Laboratory Practice-grade soluble…
- Conditions
- Leishmaniasis, Cutaneous, Leishmaniasis, Leishmaniasis, Visceral, Immunogenicity
- Trial name
- LEISHVAC (NCT07783243)
- Where
- 2 sites in Ethiopia
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Institute of Tropical Medicine, Belgium
Leishmaniasis, Cutaneous
ASYMPTOMATIC CARRIER OF LEISHMANIA INFANTUM, MEDISERRANEAN VISCERAL LEISHMANIOSIS AGENT: STUDY OF IMMUNE RESPONSE -
Leishmaniasis is considered by the WHO as emerging and uncontrolled diseases. They are the second leading cause of death and the fourth leading cause of morbidity in tropical diseases.
- Trial name
- Asymptoleish (NCT03303898)
- Testing
- Blood sampling
- Where
- France
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire de Nice
Healthy
Safety/Efficacy Trial of Killed Leishmania Vaccine in Volunteers With no Response to Leishmanin
Development of a safe and effective vaccine against leishmaniasis started more than 10 years ago under WHO/TDR supervision. An autoclaved L. major vaccine (ALM) mixed with BCG has been tested in human in Iran, Pakistan and Sudan.
- Trial name
- NCT00429715
- Testing
- Alum-ALM + BCG
- Where
- Iran
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Tehran University of Medical Sciences
Leishmaniasis
Human Leishmaniasis: Antigen Recognition Pattern and Study of New Potential Biomarkers
This is an exploratory experimental multicentre study on archived serum samples and on prospectively collected serum samples and blood samples.
- Trial name
- LeishmARPs (NCT06307171)
- Testing
- In-house Western blot, specific for Leishmania
- Where
- Italy
- Volunteers
- 170 people, healthy volunteers welcome
- Sponsor
- IRCCS Sacro Cuore Don Calabria di Negrar
Visceral Leishmaniasis, Chagas Disease
A First-in-human, Safety, Tolerability, and Pharmacokinetics Study of LXE408 in Healthy Subjects
The purpose of this first-in-human study is to generate the necessary safety, tolerability, and pharmacokinetics (PK) information that will support further clinical development of LXE408 for the treatment of patients with…
- Trial name
- NCT07809919
- Testing
- LXE408, Iohexol
- Where
- United States
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Visceral Leishmaniasis
Phase 1 LEISH-F3 + SLA-SE Vaccine Trial in Healthy Adult Volunteers
The purpose of this study is to compare the safety, tolerability, and immunogenicity in healthy adult subjects of an investigational vaccine being developed for the prevention of visceral leishmaniasis.
- Trial name
- NCT02071758
- Testing
- LEISH-F3 + SLA-SE, LEISH-F3 + GLA-SE
- Where
- United States
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Access to Advanced Health Institute (AAHI)
Leishmaniasis
Safety, Tolerability and Pharmacokinetics (PKs) Investigation of GSK3186899 in Healthy Subjects
The purpose of this study is to evaluate the safety, tolerability and PK profile of single and repeat ascending doses of GSK3186899 in healthy subjects.
- Trial name
- NCT03874234
- Testing
- GSK3186899
- Where
- United Kingdom
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Leishmaniasis
Th1/Th2 Polarization and Linkage to L. Viannia Infection Outcomes
The purpose of this study is to determine what types of cells participate in the defense of humans against Leishmania (skin parasites).
- Trial name
- NCT00401297
- Where
- Colombia
- Volunteers
- 122 people, healthy volunteers welcome
- Sponsor
- Yale University
Cutaneous Leishmaniasis
Study to Evaluate the Leish-111f + MPL-SE Vaccine in Healthy Adults Not Previously Exposed to Leishmania Parasite
This study will evaluate the safety and immunogenicity of the Leish-111f + MPL-SE vaccine in adult subjects who have no evidence of previous exposure to the Leishmania parasite.
- Trial name
- NCT00121862
- Testing
- Leish-111f + MPL-SE vaccine
- Where
- Colombia
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Access to Advanced Health Institute (AAHI)
Leishmaniasis
Mediterranean Visceral Leishmaniasis With Leishmania Infantum
L. infantum leishmaniasis is endemic in the South of France. For several years, there has been an expansion of the territory of sandflies (vector of leishmaniasis), with the appearance of cases of canine leishmaniasis in new…
- Trial name
- AsymptoGen (NCT03784248)
- Testing
- blood donation and isolation of leuco-platelet layers
- Where
- France
- Volunteers
- 1,400 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire de Nice
Visceral Leishmaniasis, Kala Azar
Efficacy, Acceptability and Cost-effectiveness of Long Lasting Insecticide Nets (LLIN) in the Prevention of Kala Azar
A cluster-randomized vector control trial in Bihar, India, and neighboring Nepal, will test the efficacy of long-lasting impregnated bednets (LLINs, Permanets) for reducing visceral leishmaniasis incidence.
- Trial name
- KALANET (NCT00318721)
- Testing
- Long Lasting Impregnated Nets (LLIN)
- Where
- 2 sites in India, Nepal
- Volunteers
- 20,000 people, healthy volunteers welcome
- Sponsor
- London School of Hygiene and Tropical Medicine
Cutaneous Leishmaniases
Complex Cutaneous Leishmaniasis Healing Study in Algeria
This study evaluates the effect of clean wound management and dressing on complex zoonotic cutaneous leishmaniasis caused by L. major in the MENA region (Algeria). The patients will participate in the wound dressing themselves.
- Trial name
- LeiClean (NCT03292835)
- Testing
- LeiProtect®
- Where
- Germany
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- K. W. Stahl
Leishmaniasis
Expression of Mif Alleles in Individuals With Leishmaniasis
CIDEIM, Centro Internacional de Entrenamiento e Investigaciones Medicas, is conducting a research study about the disease Cutaneous Leishmaniasis, which is caused by the Leishmania parasite and causes skin sores.
- Trial name
- NCT00401349
- Where
- Colombia
- Volunteers
- 438 people, healthy volunteers welcome
- Sponsor
- Yale University
Cutaneous Leishmaniasis
Safety Study to Evaluate the Leish-111f + MPL-SE Vaccine in the Prevention of Cutaneous Leishmaniasis in Healthy Subjects Previously Exposed to the Leishmania Parasite
This study will evaluate the safety of the Leish-111f + MPL-SE vaccine in adult subjects with a previous exposure to the Leishmania parasite (but without current or past history of leishmaniasis).
- Trial name
- NCT00121849
- Testing
- Leish-111f + MPL-SE vaccine
- Where
- Colombia
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Access to Advanced Health Institute (AAHI)
Leishmaniasis, Cutaneous, Vector Borne Diseases
Enhancing Protection Against Vector-borne Diseases in Forcibly Displaced Communities: Evaluating the Efficacy of Spatial Repellents for Cutaneous Leishmaniasis Control in North-East Syria
The aim of this study is to determine the efficacy of Mosquito Shield (spatial repellent) in reducing cutaneous leishmaniasis case incidence among internally displaced persons and sandfly density in temporary shelters and camp…
- Trial name
- NCT06917040
- Testing
- Spatial repellant emanator
- Where
- Syria
- Volunteers
- 18,404 people, healthy volunteers welcome
- Sponsor
- The Mentor Initiative
Leishmaniasis
Phase 1 LEISH-F3 Vaccine Trial in Healthy Adult Volunteers
The purpose of this study is to determine the safety, tolerability, and immunogenicity in healthy adult subjects of an investigational vaccine being developed for the prophylaxis of visceral leishmaniasis.
- Trial name
- NCT01484548
- Testing
- LEISH-F3 + GLA-SE, LEISH-F3 alone
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Access to Advanced Health Institute (AAHI)